Biofrontera Introduces New And Updated Websites For Its Ameluz And...

Biofrontera Introduces New And Updated Websites For Its Ameluz And Xepi

Healthcare Tech Outlook | Thursday, April 28, 2022

Biofrontera’s new and updated websites will offer product-related content for both patient-focused and healthcare professional-focused audiences.

Fremont, CA : “The launch of these websites, which as part of broader campaigns were developed and tested with external audiences, marks an important step in our initiative to enhance medical affairs and build brand awareness.” comments Erica Monaco, CEO of Biofrontera Inc. Biofrontera Inc., a biopharmaceutical business focusing in the commercialization of dermatological treatments, has launched new and updated websites for Ameluz® and Xepi®, two of its products. Each brand now has two websites, one for patients and one for healthcare professionals (HCPs), with content tailored to both audiences.

"A full team of Biofrontera employees provided multidisciplinary input for the construction of our new brand-specific websites, with fresh content and compelling graphics. Expanding our digital footprint with a patient-focused landing page is a first for Ameluz® and a significant upgrade for Xepi® that provides helpful tools and guidance for patients and prescribers to improve access, knowledge and reimbursement. Educating the industry on the importance of field therapy and the efficacy of our products is a critical component of our market expansion and commercial strategy that we believe will increase utilization of photodynamic therapy (PDT)," adds Monaco.

The new websites have designs, content, and capabilities that make it easier for patients to access information and highlight the benefits of products for prescribers. The Xepi® patient website provides simple instructions for getting Xepi® through specific pharmacies using the applicable co-pay scheme. The Ameluz® website is the first-ever patient-focused website for the drug, and it offers patients a complete description of actinic keratosis (AK) and Ameluz® treatment, as well as prescribing information and a downloadable brochure.

The Xepi® website includes an access map and an example request form for healthcare practitioners. The Ameluz® HCP website highlights the advantages of PDT field treatment for AK, as well as the first commercial preview of the RhodoLED® XL illumination lamp and physician support information on access and reimbursement.

Weekly Brief